XIV News Alert Daily Inverse VIX ST ETN Velocityshares (XIV)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Daily Inverse VIX ST ETN Velocityshares (XIV) 31.69 $XIV

SmarTrend Watching for Potential Rebound in Shares of VelocityShares Daily Inverse VIX ST ETN After 2.41% Loss
Comtex SmarTrend(R) - Tue Dec 30, 3:41PM CST
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $33.74 to a high of $34.74. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $34.32 on volume of 11.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XIV: 31.69 (+0.55)

An ETF Leveraged Pairs Strategy That 'Works' (But Would Still Be A Terrible Investment)
James Goodchild - at Seeking Alpha - Fri Dec 26, 3:46PM CST

SPXU: 38.09 (+0.05), UPRO: 132.25 (-0.36), TVIX: 2.66 (-0.10), XIV: 31.69 (+0.55)

VelocityShares Daily Inverse VIX ST ETN Rises 5.09% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Dec 22, 3:57PM CST
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $33.87 to a high of $34.94. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $33.75 on volume of 13.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XIV: 31.69 (+0.55)

The Mistakes Smaller Investors Are Making
Stock Traders Daily - at Seeking Alpha - Thu Dec 18, 1:15PM CST

TVIX: 2.66 (-0.10), VXX: 30.99 (-0.52), XIV: 31.69 (+0.55)

Look for Shares of VelocityShares Daily Inverse VIX ST ETN to Potentially Rebound after Yesterday's 5.02% Sell Off
Comtex SmarTrend(R) - Tue Dec 16, 3:50PM CST
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $29.30 to a high of $32.61. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $29.64 on volume of 35.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XIV: 31.69 (+0.55)

The Volatility Battleground
Markit - Seeking Alpha - Mon Dec 15, 6:26AM CST
Volatility has declined since the spike in October, but developments in Greece and oil price effects have disturbed the calm conditions. Volatility was the name of the game earlier in the first quarter as credit was swept up in the maelstrom...
TVIX: 2.66 (-0.10), VXX: 30.99 (-0.52), IVOP: 38.04 (-0.07), GREK: 13.74 (+0.34), UVXY: 24.33 (-0.82), ACWV: 68.66 (-0.18), VIIX: 41.81 (-0.89), XXV: 38.31 (unch), VIXY: 20.61 (-0.38), SVXY: 62.27 (+1.11), XIV: 31.69 (+0.55)

Short The Blood: Betting Against The VIX Into A Volatility Spike
Force Majeure - at Seeking Alpha - Mon Dec 15, 5:20AM CST

TVIX: 2.66 (-0.10), SPY: 205.43 (-0.11), QQQ: 102.94 (-0.31), VXX: 30.99 (-0.52), DIA: 177.94 (+0.06), XIV: 31.69 (+0.55)

After Yesterday's Decline of 1.56%, VelocityShares Daily Inverse VIX ST ETN Offers Investors Better Value
Comtex SmarTrend(R) - Tue Dec 09, 3:43PM CST
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $35.79 to a high of $38.24. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $38.00 on volume of 18.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XIV: 31.69 (+0.55)

Shares of XIV Up 24.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 08, 10:16AM CST
SmarTrend identified an Uptrend for VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) on October 21st, 2014 at $32.16. In approximately 2 months, VelocityShares Daily Inverse VIX ST ETN has returned 24.43% as of today's recent price of $40.01.
XIV: 31.69 (+0.55)

After Yesterday's Rally of 1.75% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Dec 05, 3:54PM CST
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $39.70 to a high of $40.74. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $39.78 on volume of 9.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XIV: 31.69 (+0.55)

The Best Offense Is A Good Defense: Profiting From Hedging
AllAboutAlpha - Seeking Alpha - Thu Dec 04, 4:25PM CST
This time of year one often encounters certain football-fans' truisms. Sometimes one is told "the best defense is a good offense." At other times, "the best offense is a good defense." At yet other times, "it's all in the...
TVIX: 2.66 (-0.10), VXX: 30.99 (-0.52), IVOP: 38.04 (-0.07), UVXY: 24.33 (-0.82), VIIX: 41.81 (-0.89), XXV: 38.31 (unch), VIXY: 20.61 (-0.38), SVXY: 62.27 (+1.11), XIV: 31.69 (+0.55)

Short Volatility: A Great Long-Term Investment As Always
Thomas Novak - at Seeking Alpha - Thu Dec 04, 9:51AM CST

TVIX: 2.66 (-0.10), VXX: 30.99 (-0.52), XIV: 31.69 (+0.55), SVXY: 62.27 (+1.11)

Doing The Unthinkable: Going Long Volatility
Josh Arnold - at Seeking Alpha - Thu Dec 04, 2:47AM CST

TVIX: 2.66 (-0.10), VXX: 30.99 (-0.52), UVXY: 24.33 (-0.82), XIV: 31.69 (+0.55)

Watch for VelocityShares Daily Inverse VIX ST ETN to Potentially Rebound After Falling 4.26% Yesterday
Comtex SmarTrend(R) - Mon Dec 01, 4:14PM CST
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $36.51 to a high of $37.85. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $38.40 on volume of 12.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XIV: 31.69 (+0.55)

VelocityShares Daily Inverse VIX ST ETN Shares Up 17.3% Since SmarTrend's Buy Recommendation (XIV)
Comtex SmarTrend(R) - Mon Dec 01, 9:29AM CST
SmarTrend identified an Uptrend for VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) on October 21st, 2014 at $32.16. In approximately 1 month, VelocityShares Daily Inverse VIX ST ETN has returned 17.31% as of today's recent price of $37.72.
XIV: 31.69 (+0.55)

VelocityShares Daily Inverse VIX ST ETN Rises 2.11% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Nov 24, 4:02PM CST
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $38.06 to a high of $38.73. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $38.29 on volume of 7.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XIV: 31.69 (+0.55)

Shares of XIV Up 17.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 21, 4:55PM CST
SmarTrend identified an Uptrend for VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) on October 21st, 2014 at $32.16. In approximately 1 month, VelocityShares Daily Inverse VIX ST ETN has returned 17.87% as of today's recent price of $37.90.
XIV: 31.69 (+0.55)

Look for Shares of VelocityShares Daily Inverse VIX ST ETN to Potentially Pullback after Yesterday's 1.67% Rise
Comtex SmarTrend(R) - Tue Nov 18, 4:04PM CST
VelocityShares Daily Inverse VIX ST ETN (NYSE:XIV) traded in a range yesterday that spanned from a low of $37.22 to a high of $38.12. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $37.85 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XIV: 31.69 (+0.55)

The Curious Case Of Elevated Volatility (Weight Of Evidence, Part 2 Of 7)
360 Investment Research - at Seeking Alpha - Tue Nov 18, 2:33PM CST
"Fear tends to manifest itself much quicker than greed, so volatile markets tend to be on the downside. In up markets, volatility tends to gradually decline." ~ Philip Roth The CBOE Volatility Index is often referred to as the FEAR Index....
TVIX: 2.66 (-0.10), VXX: 30.99 (-0.52), IVOP: 38.04 (-0.07), UVXY: 24.33 (-0.82), VIIX: 41.81 (-0.89), XXV: 38.31 (unch), VIXY: 20.61 (-0.38), SVXY: 62.27 (+1.11), XIV: 31.69 (+0.55)

Hot Potato: Playing Chicken With The VIX
Force Majeure - at Seeking Alpha - Mon Nov 17, 10:18AM CST

TVIX: 2.66 (-0.10), SPY: 205.43 (-0.11), QQQ: 102.94 (-0.31), VXX: 30.99 (-0.52), XIV: 31.69 (+0.55)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 50

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 84

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

Equitage Ventures Launches $47.3M Fund for Senior Care Tech

Updated Category News Views 329

Equitage Ventures Launches Significant Investment Fund Equitage Ventures, an early-stage venture capital firm dedicated to AgeTech, has announced the successful final closing of a substantial $47.3 million investment fund. This fund is designed to provide critical capital, distribution resources, and strategic guidance to innovative entrepreneurs who aim to tackle the...

Continue Reading
Understanding Market Trends: Insights into Chevron Corp's Performance

Updated Category News Views 171

Chevron Corp Market Sentiment Analysis Chevron Corp (NYSE: CVX) has experienced a noteworthy decline in its short interest as a percentage of float, showing a 10.26% decrease since its previous report. Currently, there are approximately 14.02 million shares sold short, which accounts for 0.7% of all shares available for trading. Given the trading volume, it is estimated...

Continue Reading
Establishment of Blakely McCrory Hope Fund at Moody Gardens

Updated Category News Views 200

Introducing the Blakely McCrory Hope Fund Moody Gardens is proud to announce a special initiative to honor the memory of a young girl who captured the hearts of many: the Blakely McCrory Hope Fund. This fund has been established in loving memory of 8-year-old Blakely McCrory, who lost her life in a tragic flooding incident that occurred during the summer months....

Continue Reading
Star-Studded Table Read of 'It's a Wonderful Life' Event

Updated Category News Views 221

Exciting Holiday Table Read for a Worthy Cause The Ed Asner Family Center is pulling out all the stops this holiday season with an exciting virtual table read of the beloved classic, "It's a Wonderful Life." Scheduled for December 14 at 5 PM PST, this event promises to spread joy while supporting individuals and families with special needs. Star-Studded Cast Comes...

Continue Reading
Transforming $100 Into Over $1700 with Monolithic Power Systems

Updated Category News Views 145

Understanding the Growth of Monolithic Power Systems Monolithic Power Systems (NASDAQ: MPWR) has showcased impressive financial performance over the past decade, outperforming many market benchmarks. With an impressive annualized growth rate of 19.88%, it has attracted the attention of savvy investors. The Power of Compounded Returns Imagine investing $100 in MPWR stock...

Continue Reading